Better Known as: Lexiva or Telzir
- Marketed By: Viiv Healthcare (Joint venture of Pfizer & GlaxoSmithKline)
- Major Indication: Human Immunodeficiency Virus Infection
- Drug Class: HIV Protease Inhibitor
- Date of FDA Approval (Discontinued): 2003 (2017)
- 2007 Sales: $240 Million
- Importance: As a prodrug, It is rapidly metabolized by the liver into its active form, also known as Amprenavir. As a prodrug, it is a slow release form of Amprenavir, thus requiring less frequent dosing. It was one of the first instances of a successful drug stemming from joint ventures of major pharmaceutical companies.
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Fosamprenavir is a potent HIV Protease inhibitor. As a prodrug form of Amprenavir, it has an identical mechanism of action as Amprenavir.
Drug Resistance
The biggest difficulty with treating HIV is the rapidity at which it mutates and becomes resistant to treatments. To view a comprehensive and interactive analysis of the mutations which confer drug resistance to HIV Protease, See: HIV Protease Inhibitor Resistance Profile
